Osteoporosis Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Route of Administration (Oral, Injectables, Others), By Drug Type (Parathyroid Hormone Therapy, Bisphosphonates, Calcitonin, Selective Estrogen Receptor Modulators, Others), By Region and Competition, 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 14.33 Billion
CAGR (2026-2031)	4.24%
Fastest Growing Segment	Oral
Largest Market	North America
Market Size (2031)	USD 18.38 Billion

Market Overview

The Global Osteoporosis Drugs Market is projected to grow from USD 14.33 Billion in 2025 to USD 18.38 Billion by 2031 at a 4.24% CAGR. Osteoporosis drugs encompass pharmaceutical agents formulated to prevent bone loss, augment bone mineral density, and reduce the incidence of fractures in individuals diagnosed with osteoporosis. The expansion of the global osteoporosis drugs market is principally driven by an aging worldwide population, the increasing prevalence of osteoporosis, continuous advancements in diagnostic capabilities, and heightened awareness regarding bone health. According to the International Osteoporosis Foundation, in October 2025, up to 80% of patients who suffered an osteoporotic fracture remained undiagnosed and untreated for the underlying condition, highlighting a significant opportunity for therapeutic intervention.

Nevertheless, a key challenge constraining market growth involves issues surrounding patient adherence to long-term treatment protocols, often exacerbated by the asymptomatic nature of the disease. Furthermore, the elevated cost associated with advanced therapeutic options and potential side effect profiles of certain medications also present obstacles to broader market penetration.

Key Market Drivers

The rising global prevalence of osteoporosis and related fractures serves as a primary driver for the expansion of the osteoporosis drugs market. This pervasive bone disorder significantly increases the risk of bone fragility, leading to a higher incidence of fractures worldwide and consequently, a greater demand for therapeutic interventions. According to the International Osteoporosis Foundation, in October 2025, more than 37 million fractures due to fragile bones occur in people over 55 each year, underscoring the substantial patient population requiring effective pharmacological management to mitigate fracture risk and improve bone mineral density. This widespread occurrence creates a continuous need for both existing and novel drug therapies.

Concurrently, the increasing geriatric population worldwide is a critical factor propelling market growth, as older individuals are inherently more susceptible to osteoporosis. As global life expectancy rises, the proportion of elderly people expands, leading to a larger demographic at risk of developing the condition. According to the World Health Organization, in February 2025, the number of people aged 60 and older worldwide is projected to increase from 1.1 billion in 2023 to 1.4 billion by 2030, directly contributing to an amplified patient pool for osteoporosis drugs. This demographic shift intensifies the burden on healthcare systems; according to Capture the Fracture, in 2025, fragility fractures cost global healthcare systems $400 billion.

Download Free Sample Report

Key Market Challenges

A significant challenge constraining the expansion of the global osteoporosis drugs market stems from issues surrounding patient adherence to long-term treatment protocols. This challenge is often exacerbated by the asymptomatic nature of osteoporosis, meaning individuals may not perceive an immediate benefit from medication or recognize the ongoing need for therapy in the absence of symptoms. Consequently, many patients discontinue treatment prematurely, directly hindering the effectiveness of prescribed pharmaceutical interventions.

Poor patient adherence directly hampers market growth by reducing the overall consumption and sustained demand for osteoporosis drugs. According to the International Osteoporosis Foundation, in August 2025, approximately 20–30% of patients never even initiate their prescribed oral bisphosphonate treatment, and among those who do, about 40% discontinue within the first year. This substantial rate of non-adherence leads to an increased risk of fractures and diminished patient outcomes, ultimately limiting the market's potential as drugs are not fully utilized to prevent disease progression or reduce fracture incidence over the long term.

Key Market Trends

The global osteoporosis drugs market is significantly influenced by a pronounced shift towards advanced biologics and anabolic agents, representing a move towards more potent and targeted therapies. These newer agents offer distinct mechanisms of action, such as bone formation stimulation, which contrasts with traditional antiresorptive treatments. This evolution provides clinicians with improved options for patients with severe osteoporosis or those who have not responded adequately to conventional therapies, potentially leading to better patient outcomes and reduced fracture risk. According to Amgen's Fourth Quarter and Full Year 2025 Financial Results, published in February 2026, sales of EVENITY (romosozumab-aqqg), an anabolic agent, increased by 34% for the full year 2025, underscoring the growing market penetration and clinical adoption of these advanced treatments.

Concurrently, the increased availability of biosimilars is profoundly reshaping market dynamics by introducing more affordable alternatives to established biologic therapies. This trend enhances patient access, particularly in regions constrained by healthcare budgets, and intensifies competition among manufacturers. The entry of biosimilars typically leads to price reductions, which can expand the overall treatable patient population and encourage greater adherence to long-term treatment protocols by alleviating financial burdens. In 2025, the European Medicines Agency approved 23 denosumab biosimilars, highlighting a substantial expansion in the availability of cost-effective options for a widely used osteoporosis biologic.

Segmental Insights

The oral segment is a pivotal driver in the global osteoporosis drugs market, demonstrating rapid growth attributable to several factors. This segment benefits significantly from its wide availability and extensive distribution channels across both developed and emerging markets, making therapies easily accessible to a broad patient population. Healthcare professionals often prefer established oral medications, such as bisphosphonates, which are supported by strong clinical evidence and have a long history of effective use as first-line treatments. Moreover, the inherent convenience and ease of administration associated with oral formulations enhance patient adherence, contributing to their expanding adoption. The comparative affordability of oral drugs also makes them an attractive option, fostering their increasing market presence.

Regional Insights

North America leads the global osteoporosis drugs market due to a combination of distinct factors. The region benefits from a significant aging population, particularly postmenopausal women, who are highly susceptible to osteoporosis and related fractures. This demographic trend fuels consistent demand for effective treatments. Furthermore, North America possesses a highly developed healthcare infrastructure, coupled with high per capita healthcare expenditure, which facilitates early disease detection and comprehensive treatment adoption. High awareness of bone health among both the public and medical professionals, alongside the presence of leading pharmaceutical companies and robust regulatory support from bodies like the U.S. Food and Drug Administration, further solidify its market leadership through continuous innovation and widespread access to advanced therapies.

Recent Developments

• In April 2026, Biocon Limited commercially launched two denosumab biosimilars, Bosaya™ and Aukelso™, in the United States. Bosaya™ is a biosimilar to Prolia®, and Aukelso™ is a biosimilar to Xgeva®, both targeting osteoporosis and associated bone complications. These new product introductions expand treatment options for patients requiring therapies to manage bone health. The company's strategic expansion of its biosimilars portfolio aims to enhance access to high-quality, affordable medications for individuals with serious bone conditions across the nation.
• In April 2026, Apotex Inc. received Health Canada approval for DENOZA™ (denosumab injection), a biosimilar to Prolia®. This approval provides an additional treatment option for postmenopausal women and men with osteoporosis who are at high risk for fracture in Canada. The introduction of DENOZA™ underscores Apotex's ongoing commitment to improving access to essential therapies and contributing to a sustainable healthcare system by offering more choices for patients and healthcare professionals in the management of osteoporosis.
• In January 2026, researchers at the University of Hong Kong's LKS Faculty of Medicine (HKUMed) announced a breakthrough in understanding bone health. They identified a protein, Piezo1, that functions as the body's 'exercise sensor', translating physical movement into signals vital for bone strength. This discovery in bone biology holds potential for future drug development in the global osteoporosis drugs market. It suggests the possibility of creating new therapies that could mimic the bone-strengthening effects of exercise, particularly benefiting patients with limited mobility or those unable to engage in physical activity.
• In December 2025, a significant regulatory advancement impacting the global osteoporosis drugs market occurred as the U.S. Food and Drug Administration (FDA) qualified image-based biomarkers of bone mineral density (BMD) as a surrogate endpoint for bone fractures in clinical trials for osteoporosis medicines. This decision is expected to streamline and expedite the development of new osteoporosis medications. This breakthrough research resulted from a large-scale global collaboration involving institutions such as the University of Sheffield, Harvard Medical School, and the University of California, San Francisco. The regulatory change is anticipated to encourage renewed investment in developing innovative osteoporosis treatments, ultimately accelerating patient access to new therapies.

Key Market Players

• Eli Lilly and Company
• Pfizer Inc.
• F. Hoffmann-La Roche Ltd
• Teva Pharmaceutical Industries Ltd.
• GlaxoSmithKline plc.
• Novartis International AG
• Merck & Co. Inc.
• Amgen Inc.
• Radius Health Inc.
• Actavis PLC

By Route of Administration	By Drug Type	By Region
Oral Injectables Others	Parathyroid Hormone Therapy Bisphosphonates Calcitonin Selective Estrogen Receptor Modulators Others	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Osteoporosis Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Osteoporosis Drugs Market, By Route of Administration:

• Oral
• Injectables
• Others

• Osteoporosis Drugs Market, By Drug Type:

• Parathyroid Hormone Therapy
• Bisphosphonates
• Calcitonin
• Selective Estrogen Receptor Modulators
• Others

• Osteoporosis Drugs Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE